Clinical Trials | June 14, 2026
Breakthrough approval in prostate cancer for AstraZeneca therapy
The decision was driven by results from the Phase III CAPItello-281 trial,
The decision was driven by results from the Phase III CAPItello-281 trial,
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
Clearance marks major shift beyond chemotherapy
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
The decision is based on the phase 3 DESTINY-Breast11 trial
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
